Publicacións nas que colabora con Francisco Javier Narváez García (69)

2024

  1. Incidence and clinical manifestations of giant cell arteritis in Spain: results of the ARTESER register

    RMD open, Vol. 10, Núm. 1

  2. Risk loci involved in giant cell arteritis susceptibility: a genome-wide association study

    The Lancet Rheumatology, Vol. 6, Núm. 6, pp. e374-e383

2023

  1. Mucosal Immune Defence Gene Polymorphisms as Relevant Players in the Pathogenesis of IgA Vasculitis?

    International Journal of Molecular Sciences, Vol. 24, Núm. 17

  2. Optimisation of tocilizumab therapy in giant cell arteritis. A multicentre real-life study of 471 patients

    Clinical and experimental rheumatology, Vol. 41, Núm. 4, pp. 829-836

  3. Pregnancy outcomes in 1869 pregnancies in a large cohort from the Spanish Society of Rheumatology Lupus Register (RELESSER)

    Seminars in Arthritis and Rheumatism, Vol. 61

  4. Screening criteria for interstitial lung disease associated to rheumatoid arthritis: Expert proposal based on Delphi methodology

    Reumatologia Clinica, Vol. 19, Núm. 2, pp. 74-81

2022

  1. Antimalarials exert a cardioprotective effect in lupus patients: Insights from the Spanish Society of Rheumatology Lupus Register (RELESSER) analysis of factors associated with heart failure

    Seminars in Arthritis and Rheumatism, Vol. 52

  2. Biologic therapy in refractory neurobehçet's disease: a multicentre study of 41 patients and literature review

    Rheumatology (Oxford, England), Vol. 61, Núm. 11, pp. 4427-4436

  3. IgA Vasculitis: Influence of CD40, BLK and BANK1 Gene Polymorphisms

    Journal of Clinical Medicine, Vol. 11, Núm. 19

  4. Tocilizumab in visual involvement of giant cell arteritis: a multicenter study of 471 patients

    Therapeutic Advances in Musculoskeletal Disease, Vol. 14

2021

  1. Abatacept in monotherapy vs combined in interstitial lung disease of rheumatoid arthritis-multicentre study of 263 Caucasian patients

    Rheumatology (Oxford, England), Vol. 61, Núm. 1, pp. 299-308

  2. BAFF, APRIL and BAFFR on the pathogenesis of Immunoglobulin-A vasculitis

    Scientific Reports, Vol. 11, Núm. 1

  3. Do all antiphospholipid antibodies confer the same risk for major organ involvement in systemic lupus erythematosus patients?

    Clinical and Experimental Rheumatology, Vol. 39, Núm. 3, pp. 555-563

  4. HLA association with the susceptibility to anti-synthetase syndrome

    Joint Bone Spine, Vol. 88, Núm. 3

  5. Influence of prognosis factors on the prescription of targeted treatments in rheumatoid arthritis: A Delphi survey

    Joint Bone Spine, Vol. 88, Núm. 4

  6. Relevance of gastrointestinal manifestations in a large Spanish cohort of patients with systemic lupus erythematosus: what do we know?

    Rheumatology (Oxford, England), Vol. 60, Núm. 11, pp. 5329-5336

  7. Tocilizumab in refractory Caucasian Takayasu’s arteritis: a multicenter study of 54 patients and literature review

    Therapeutic Advances in Musculoskeletal Disease, Vol. 13

  8. Tocilizumab in refractory giant cell arteritis. Monotherapy versus combined therapy with conventional immunosuppressive drugs. Observational multicenter study of 134 patients

    Seminars in Arthritis and Rheumatism, Vol. 51, Núm. 2, pp. 387-394

2020

  1. Apremilast in refractory orogenital ulcers and other manifestations of Behçet's disease. A national multicentre study of 51 cases in clinical practice

    Clinical and experimental rheumatology, Vol. 38, Núm. 5, pp. 69-75

  2. Biologic therapy in refractory non-multiple sclerosis optic neuritis isolated or associated to immune-mediated inflammatory diseases. A multicenter study

    Journal of Clinical Medicine, Vol. 9, Núm. 8, pp. 1-13